Funded Biotechnology Startups in Miami
Disclosed funding amounts in this Miami biotechnology list are highly uneven: Veru’s $33M round (2023-12-14) is the largest disclosed amount, and it substa…
Disclosed funding amounts in this Miami biotechnology list are highly uneven: Veru’s $33M round (2023-12-14) is the largest disclosed amount, and it substantially exceeds the next-largest disclosed entries of $30M (Longeveron, 2026-03-10) and $33M? [note: largest is $33M, second is $30M]. Most other disclosed rounds are comparatively smaller, including $4M (Organicell Regenerative Medicine, 2022-07-20), $12M (DermaSensor Inc., 2020-06-04), and $2M (CellVax Therapeutics Inc., 2024-10-04).
Timing and metadata also cluster. The 10 most recent rows span 2020-06-04 (DermaSensor Inc.) to 2026-06-09 (AllerGene AI Therapeutics). Stage labels are frequently unspecified: five of the 10 entries are “Series Unknown” (Aegle Therapeutics 2026-03-03, Gibson Oncology 2025-07-08, CellVax Therapeutics 2024-10-04, Veru 2023-12-14, and Longeveron 2026-03-10? [note: Longeveron is Series Unknown], with Weo as Series A 2023-03-21 and “Seed” appearing for Ambulero 2021-01-25 and AllerGene AI Therapeutics 2026-06-09). Undisclosed amounts appear twice (AllerGene AI Therapeutics 2026-06-09; Weo 2023-03-21).
Most recent rounds
10 shownRelated listings
Frequently asked
What stands out as the largest disclosed biotech round in Miami here, and how does it compare to nearby disclosed deals?
Veru’s disclosed $33M round on 2023-12-14 is the largest disclosed amount in the table, with Longeveron at $30M on 2026-03-10 as the next-largest disclosed entry; most other disclosed amounts are far lower, such as $12M (DermaSensor Inc., 2020-06-04) and $4M (Organicell Regenerative Medicine, 2022-07-20).
Do these funding events cluster into a recent date window or spread across the years?
They span multiple years, from DermaSensor Inc. on 2020-06-04 through AllerGene AI Therapeutics on 2026-06-09. Within the most recent half, there are multiple 2026-dated entries (AllerGene AI Therapeutics 2026-06-09; Longeveron 2026-03-10; Aegle Therapeutics 2026-03-03), while earlier years include Ambulero in 2021 (2021-01-25) and Organicell Regenerative Medicine in 2022 (2022-07-20).
How often are the rounds’ stage types or amounts unspecified, and does that limit comparability?
Stage classification is frequently unspecified: five of 10 rows are labeled “Series Unknown” (Aegle Therapeutics 2026-03-03, Gibson Oncology 2025-07-08, CellVax Therapeutics 2024-10-04, Veru 2023-12-14, and Longeveron 2026-03-10). Amounts are also sometimes missing: two rows show “undisclosed” (AllerGene AI Therapeutics 2026-06-09; Weo 2023-03-21).
What stage mix dominates across the 10 entries when you look beyond the unspecified labels?
Outside “Series Unknown,” Seed appears twice (AllerGene AI Therapeutics 2026-06-09; Ambulero 2021-01-25) and there is one Series A (Weo 2023-03-21) plus one Post-IPO Equity (Organicell Regenerative Medicine 2022-07-20). DermaSensor Inc. shows an empty stage field on 2020-06-04, which adds another category outside the named stage labels.
Are there outliers in either disclosed size or metadata that a diligence workflow should flag first?
Two kinds of outliers show up: disclosed-size outliers (Veru’s $33M on 2023-12-14 versus smaller disclosed rounds like $250K for Gibson Oncology on 2025-07-08) and disclosure outliers where the amount is not provided (AllerGene AI Therapeutics on 2026-06-09; Weo on 2023-03-21). The missing-amount rows can’t be compared directly to the disclosed range that includes $460K (Aegle Therapeutics, 2026-03-03) and $30M (Longeveron, 2026-03-10).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.